A study using a mouse model with combined mutation of TET2, FLT3-ITD, and IDH2-R140Q; thus, triple-transformed leukemia, showed tumor sensitivity both to 5-azacytidine and to IDH2 inhibitor enasidenib. Here, IDH2 is linked to leukemia.